BURLINGAME, Calif.–(BUSINESS WIRE)–Pulse Biosciences, Inc., (NASDAQ:PLSE), a medical technology company developing a proprietary therapeutic treatment platform based on Nano-Pulse Stimulation (NPS), today announced the results of three preclinical studies that further validate the NPS technology and its potential role in novel immunotherapeutic approaches. The new data, which will be presented …
Tag Archives: nps pharmaceuticals
November, 2016
January, 2015
-
26 January
Shire Gains as FDA Approves NPS Pharma’s Endocrine Disorder Drug
On Friday, the US Food and Drug Administration (FDA) approved NPS Pharmaceuticals’ rare endocrine disorder drug Natpara (parathyroid hormone), justifying Shire’s $5.2 billion acquisition of the company. The agency approved NPS’ Natpara to control hypocalcemia (low blood calcium levels) in patients with hypoparathyroidism, a rare disease that affects approximately 60,000 …
-
13 January
Shire Acquires Rare Disease Company NPS Pharma
Dublin-based Shire has agreed to use its AbbVie breakup fee to acquire rare disease drugmaker NPS Pharmaceuticals, Inc. The companies announced that they have entered into a merger agreement, under which Shire will acquire all the outstanding shares of NPS Pharma for $46 per share in cash, for a total …